Oral sulphonylureas in the management of diabetes.
D000092:Acetohexamide / Q000627:therapeutic use; D002747:Chlorpropamide / Q000008:administration & dosage / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004702:Endocrine Glands / Q000187:drug effects; D005951:Glucose Tolerance Test; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009765:Obesity; D011743:Pyrimidines / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D013451:Sulfonic Acids / Q000627:therapeutic use; D014042:Tolazamide / Q000627:therapeutic use; D014044:Tolbutamide / Q000008:administration & dosage / Q000627:therapeutic use; D014508:Urea / Q000627:therapeutic use; D014652:Vascular Diseases / Q000139:chemically induced
D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D011743:Pyrimidines; D013450:Sulfones; D013451:Sulfonic Acids; D014508:Urea; D014044:Tolbutamide; D014042:Tolazamide; D000092:Acetohexamide; D002747:Chlorpropamide